Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, Neuroblastoma Research and Treatments, and Melanoma and MAPK Pathways.
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer
Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15–39): A Qualitative Study
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group
Characterization of on-target adverse events caused by TRK inhibitor therapy
COVID‐19 disease in New York City pediatric hematology and oncology patients
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout disease
Unrealistic parental expectations for cure in poor‐prognosis childhood cancer
A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <i>RET</i>-altered cancers.
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
Integrated analysis of long‐term growth and bone development in pediatric and adolescent patients receiving bevacizumab
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
Emerging and investigational therapies for neuroblastoma
Clinical trial enrollment of adolescents and young adults with sarcoma
Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis.
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors
Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer
Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer
Translating genomic discoveries to the clinic in pediatric oncology